Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
H.R. 946 / S. 1862, Orphan Cures Act implementation H.R. 1262 Give Kids a Chance Act Issues related to Medicaid rebates Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
H.R. 946 / S. 1862, Orphan Cures Act implementation H. Res. 1331, Expressing support for "Hidradenitis Suppurativa Awareness Week" S. 2658, Medication Affordability and Patent Integrity Act Issues related to Medicaid rebates Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
INCYTE CORPORATION via INCYTE CORPORATION
2026 · third_quarter · Q3
H.R. 946 / S. 1862, Orphan Cures Act implementation H. Res. 1331, Expressing support for "Hidradenitis Suppurativa Awareness Week" Issues related to Medicaid rebates Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Source: Senate LDA
H.R. 946 / S. 1862, Orphan Cures Act implementation H. Res. 1331, Expressing support for "Hidradenitis Suppurativa Awareness Week" Issues related to Medicaid rebates Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
H.R. 946 / S. 1862, Orphan Cures Act implementation H.R. 1262 Give Kids a Chance Act Issues related to Medicaid rebates Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
Expressing support for the designation of June 1, 2026, through June 7, 2026, as "Hidradenitis Suppurativa Awareness Week".
Client: INCYTE CORPORATION · Firm: INCYTE CORPORATION
H.R. 946 / S. 1862, Orphan Cures Act implementation H. Res. 1331, Expressing support for "Hidradenitis Suppurativa Awareness Week" Issues related to Medicaid rebates Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
Expressing support for the designation of June 1, 2026, through June 7, 2026, as "Hidradenitis Suppurativa Awareness Week".
Client: INCYTE CORPORATION · Firm: INCYTE CORPORATION
H.R. 946 / S. 1862, Orphan Cures Act implementation H. Res. 1331, Expressing support for "Hidradenitis Suppurativa Awareness Week" S. 2658, Medication Affordability and Patent Integrity Act Issues related to Medicaid rebates Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
H.R. 946 / S. 1862, Orphan Cures Act implementation H.R. 1262 Give Kids a Chance Act Issues related to Medicaid rebates Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
H.R. 946 / S. 1862, Orphan Cures Act implementation H. Res. 1331, Expressing support for "Hidradenitis Suppurativa Awareness Week" S. 2658, Medication Affordability and Patent Integrity Act Issues related to Medicaid rebates Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
H.R. 946 / S. 1862, Orphan Cures Act implementation H. Res. 1331, Expressing support for "Hidradenitis Suppurativa Awareness Week" Issues related to Medicaid rebates Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
Medication Affordability and Patent Integrity Act
Client: INCYTE CORPORATION · Firm: INCYTE CORPORATION
H.R. 946 / S. 1862, Orphan Cures Act implementation H. Res. 1331, Expressing support for "Hidradenitis Suppurativa Awareness Week" S. 2658, Medication Affordability and Patent Integrity Act Issues related to Medicaid rebates Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
HR 946, Orphan Cures Act HR 1262, Give Kids a Chance Act of 2025 Issues related to Medicaid rebates Education around access to innovative therapies in dermatology
H.R. 946/S. 1862, Orphan Cures Act implementation H.R. 1262 Give Kids a Chance Act Issues related to Medicaid rebates Issues related to Medicaid coverage of new drugs Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
H.R. 946/S. 1862, Orphan Cures Act implementation H.R. 1262 Give Kids a Chance Act Issues related to Medicaid rebates Issues related to Medicaid coverage of new drugs Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
H.R. 946/S. 1862, Orphan Cures Act H.R. 1262, Give Kids a Chance Act Issues related to Medicaid rebates Issues related to Medicaid coverage of new drugs Issues related to implementation of the Inflation Reduction Act Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
H.R. 946/S. 1862, Orphan Cures Act implementation H.R. 1262 Give Kids a Chance Act Issues related to Medicaid rebates Issues related to Medicaid coverage of new drugs Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
H.R. 946/S. 1862, Orphan Cures Act H.R. 1262, Give Kids a Chance Act Issues related to Medicaid rebates Issues related to Medicaid coverage of new drugs Issues related to implementation of the Inflation Reduction Act Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
H.R. 946/S. 1862, Orphan Cures Act implementation H.R. 1262 Give Kids a Chance Act Issues related to Medicaid rebates Issues related to Medicaid coverage of new drugs Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
HR 946, Orphan Cures Act HR 1262, Give Kids a Chance Act of 2025 Issues related to Medicaid rebates Education around access to innovative therapies in dermatology
H.R. 946/S. 1862, Orphan Cures Act implementation H.R. 1262 Give Kids a Chance Act Issues related to Medicaid rebates Issues related to Medicaid coverage of new drugs Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
H.R. 946/S. 1862, Orphan Cures Act H.R. 1262, Give Kids a Chance Act Issues related to Medicaid rebates Issues related to Medicaid coverage of new drugs Issues related to implementation of the Inflation Reduction Act Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
H.R. 946/S. 1862, Orphan Cures Act implementation H.R. 1262 Give Kids a Chance Act Issues related to Medicaid rebates Issues related to Medicaid coverage of new drugs Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
Issues: Issues related to Medicaid rebates, H.R. 3433 The Give Kids a Chance Act
Issues: Issues related to Medicaid rebates, H.R. 3433 The Give Kids a Chance Act
H.R. 5376 - Build Back Better, Subtitle J, issues relating to Medicare Part D and Part B Pricing Reform; Issues related to capping out-of-pocket costs.
H.R. 5376 - Build Back Better, Subtitle J, issues relating to Medicare Part D and Part B Pricing Reform; Issues related to capping out-of-pocket costs.
H.R. 5376 - Build Back Better, Subtitle J, issues relating to Medicare Part D and Part B Pricing Reform; Issues related to capping out-of-pocket costs.
2026 · second_quarter · Q2
H.R. 946 / S. 1862, Orphan Cures Act implementation H. Res. 1331, Expressing support for "Hidradenitis Suppurativa Awareness Week" S. 2658, Medication Affordability and Patent Integrity Act Issues related to Medicaid rebates Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
INCYTE CORPORATION via INCYTE CORPORATION
2026 · first_quarter · Q1
H.R. 946 / S. 1862, Orphan Cures Act implementation H.R. 1262 Give Kids a Chance Act Issues related to Medicaid rebates Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
INCYTE CORPORATION via INCYTE CORPORATION
2025 · fourth_quarter · Q4
H.R. 946/S. 1862, Orphan Cures Act implementation H.R. 1262 Give Kids a Chance Act Issues related to Medicaid rebates Issues related to Medicaid coverage of new drugs Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
INCYTE CORPORATION via INCYTE CORPORATION
2025 · third_quarter · Q3
H.R. 946/S. 1862, Orphan Cures Act implementation H.R. 1262 Give Kids a Chance Act Issues related to Medicaid rebates Issues related to Medicaid coverage of new drugs Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INCYTE CORPORATION via INCYTE CORPORATION
2025 · second_quarter · Q2
H.R. 946/S. 1862, Orphan Cures Act H.R. 1262, Give Kids a Chance Act Issues related to Medicaid rebates Issues related to Medicaid coverage of new drugs Issues related to implementation of the Inflation Reduction Act Issues related to drug cost and pricing Education around access to innovative therapies in dermatology
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INCYTE CORPORATION via INCYTE CORPORATION
2025 · first_quarter · Q1
HR 946, Orphan Cures Act HR 1262, Give Kids a Chance Act of 2025 Issues related to Medicaid rebates Education around access to innovative therapies in dermatology
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INCYTE CORPORATION via INCYTE CORPORATION
2024 · fourth_quarter · 4A
Issues: Issues related to Medicaid rebates, H.R. 3433 The Give Kids a Chance Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INCYTE CORPORATION via INCYTE CORPORATION
2024 · fourth_quarter · Q4
Issues: Issues related to Medicaid rebates, H.R. 3433 The Give Kids a Chance Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INCYTE CORPORATION via INCYTE CORPORATION
2024 · third_quarter · Q3
Issues related to Medicaid Rebates
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INCYTE CORPORATION via INCYTE CORPORATION
2024 · second_quarter · Q2
Issues related to Medicaid Rebates
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INCYTE CORPORATION via INCYTE CORPORATION
2024 · first_quarter · Q1
Issues related to Medicaid Rebates
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INCYTE CORPORATION via INCYTE CORPORATION
2023 · fourth_quarter · 4A
Issues related to Medicaid Rebates
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INCYTE CORPORATION via INCYTE CORPORATION
2023 · fourth_quarter · Q4
Issues related to Medicaid Rebates
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INCYTE CORPORATION via INCYTE CORPORATION
2023 · third_quarter · Q3
Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); Issues relating to Medicare Part D and Part B pricing reform; Issues related to Medicaid Rebates; Issues related to 340B; Issues related to coverage decisions in FEP
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INCYTE CORPORATION via INCYTE CORPORATION
2023 · second_quarter · Q2
Issues relating to implementation of drug pricing and reimbursement of prescription drug provisions in The Inflation Reduction Act Issues relating to 340B Issues related to PBMs
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INCYTE CORPORATION via INCYTE CORPORATION
2023 · first_quarter · Q1
Issues relating to implementation of drug pricing and reimbursement of prescription drug provisions in The Inflation Reduction Act Issues relating to 340B Issues relating to importation of non-human primates
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INCYTE CORPORATION via INCYTE CORPORATION
2022 · fourth_quarter · Q4
Inflation Reduction Act of 2022 (PL 117-169), Subtitle B - Prescription Drug Pricing Reform; Issues related to 340B
Issues related to intellectual property
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INCYTE CORPORATION via INCYTE CORPORATION
2022 · third_quarter · Q3
Inflation Reduction Act of 2022 (PL 117-169), Subtitle B - Prescription Drug Pricing Reform; Issues related to 340B
Issues related to intellectual property
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INCYTE CORPORATION via INCYTE CORPORATION
2022 · second_quarter · 2A
Issues related to tax reform
H.R. 5376 - Build Back Better, Subtitle J, issues relating to Medicare Part D and Part B Pricing Reform; Issues related to capping out-of-pocket costs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INCYTE CORPORATION via INCYTE CORPORATION
2022 · second_quarter · Q2
Issues related to tax reform
H.R. 5376 - Build Back Better, Subtitle J, issues relating to Medicare Part D and Part B Pricing Reform; Issues related to capping out-of-pocket costs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INCYTE CORPORATION via INCYTE CORPORATION
2022 · first_quarter · Q1
H.R. 5376 - Build Back Better, Subtitle J, issues relating to Medicare Part D and Part B Pricing Reform; Issues related to capping out-of-pocket costs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INCYTE CORPORATION via INCYTE CORPORATION
2021 · fourth_quarter · 4A
Issues related to tax reform; Issues relating to Medicare Part D Pricing Reform; Issues relating to Medicare Part B pricing reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INCYTE CORPORATION via INCYTE CORPORATION
2021 · fourth_quarter · Q4
Issues related to tax reform; Issues relating to Medicare Part D Pricing Reform; Issues relating to Medicare Part B pricing reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INCYTE CORPORATION via INCYTE CORPORATION
2021 · third_quarter · Q3
Issues related to tax reform; Issues relating to Medicare Part D Pricing Reform; Issues relating to Medicare Part B pricing reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INCYTE CORPORATION via INCYTE CORPORATION
2021 · second_quarter · Q2
Issues related to 340B (contract pharmacy provisions); Issues relating to Medicare Part D Pricing Reform; Issues relating to Medicare Part B pricing reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INCYTE CORPORATION via INCYTE CORPORATION
2021 · first_quarter · Q1
Issues related to 340B (contract pharmacy provisions); Issues relating to Medicare Part D Pricing Reform; Issues relating to Medicare Part B pricing reform; Issues related to Part B refunds for discarded amounts of certain single-dose container or single-use package drugs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INCYTE CORPORATION via INCYTE CORPORATION
2021 · first_quarter · RR
Issues related to 340B (contract pharmacy provisions); drug pricing; out of pocket costs in Medicare Part D and importation